Literature DB >> 30028264

Hemi-laryngopharyngeal spasm as a novel cause of inducible laryngeal obstruction with a surgical cure: report of 3 cases.

Christopher R Honey1, Murray D Morrison2, Manraj K S Heran3, Baljinder S Dhaliwal4.   

Abstract

Inducible laryngeal obstruction has been described under at least 40 different monikers, including vocal cord dysfunction, paroxysmal vocal fold motion, and irritable larynx. The etiology of this condition is believed to be laryngeal hyperactivity in response to psychological issues or acid reflux. Most patients are treated with some combination of proton pump inhibitors, speech therapy, and psychotherapy. However, a small cohort of patients remains refractory to all medical interventions. The authors describe a novel condition, hemi-laryngopharyngeal spasm (HELPS), which can cause severe episodic stridor leading to unconsciousness in association with cough. The first recognized and surgically cured patient with HELPS was reported in an earlier issue of this journal. Three additional patients have been followed up for at least a year postoperatively, and their cases are reported here.Each patient presented with a similar pattern of episodic coughing and choking that increased in frequency, severity, and duration over years. The episodes eventually occurred while sleeping and could cause severe stridor with loss of consciousness. All three patients were initially misdiagnosed with a psychiatric illness and subjected to multiple intubations and one tracheostomy. Unilateral botulinum toxin injections in the vocal fold eased the severity of the throat contractions but not the cough. Magnetic resonance imaging showed a looping posterior inferior cerebellar artery juxtaposed to a vagus nerve in each case. Microvascular decompression (MVD) of that vessel relieved all symptoms.The introduction of this new medical condition may help a small cohort of patients with inducible laryngeal obstructions that have not responded to the current standard treatments. Patients are asymptomatic between episodes of progressively severe coughing and choking with stridor that may lead to intubation. Severe anxiety about the unpredictable symptoms is expected and may contribute to a psychiatric misdiagnosis. Microvascular decompression for HELPS is more difficult than that for trigeminal neuralgia because the involved nerve is more susceptible to manipulation. Ultimately, the final proof that HELPS is a real and distinct syndrome will require its recognition and successful treatment by colleagues around the world.

Entities:  

Keywords:  CN = cranial nerve; GPN = glossopharyngeal neuralgia; HELPS; HELPS = hemi-laryngopharyngeal spasm; HFS = hemifacial spasm; MVD = microvascular decompression; PICA = posterior inferior cerebellar artery; PVFM = paradoxical vocal fold motion; VCD = vocal cord dysfunction; hemi-laryngopharyngeal spasm; inducible laryngeal obstruction; microvascular decompression; pain; paradoxical vocal fold motion; vocal cord dysfunction

Year:  2018        PMID: 30028264     DOI: 10.3171/2018.2.JNS172952

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  3 in total

1.  Imaging and Surgical Findings in Patients with Hemi-Laryngopharyngeal Spasm and the Potential Role of MRI in the Diagnostic Work-Up.

Authors:  J Avecillas-Chasin; M G Kozoriz; J R Shewchuk; M K S Heran; C R Honey
Journal:  AJNR Am J Neuroradiol       Date:  2018-10-25       Impact factor: 3.825

Review 2.  Concurrent Glossopharyngeal Neuralgia and Hemi-Laryngopharyngeal Spasm (HeLPS): A Case Report and a Review of the Literature.

Authors:  C Michael Honey; Marie T Krüger; Alan R Rheaume; Josue M Avecillas-Chasin; Murray D Morrison; Christopher R Honey
Journal:  Neurosurgery       Date:  2020-10-15       Impact factor: 4.654

Review 3.  Clinical Importance of the Posterior Inferior Cerebellar Artery: A Review of the Literature.

Authors:  Hui-Lei Miao; Deng-Yan Zhang; Tao Wang; Xiao-Tian Jiao; Li-Qun Jiao
Journal:  Int J Med Sci       Date:  2020-10-18       Impact factor: 3.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.